

## 1<sup>ST</sup> ENOS INVESTIGATOR MEETING - GENEVA

**T**he ENOS acronym stands for "Efficacy of Nitric Oxide in Stroke". This study is an international, multicentre, trial investigating the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping prior antihypertensive therapy, in patients with acute ischaemic or haemorrhagic stroke.

### 1<sup>ST</sup> INVESTIGATOR MEETING

The ENOS trial recently had its 1<sup>st</sup> Investigator Meeting at the European Stroke Conference in Geneva. We are grateful to the many representatives from nations such as Australia, Canada, Indonesia, Latvia, Singapore, South Africa, UK and the USA, who were able to attend and helped make this a great success.

This year's 11<sup>th</sup> European Stroke Conference was also the venue for the announcement of some important pilot data for the ENOS trial<sup>1</sup>. In a 90 patient randomised controlled trial of GTN patches, those that received a 5mg GTN patch had significantly lower 24 hour systolic BP and diastolic BP (-6.3%/-4.8%). There was no effect on indirect measures of cerebral blood flow, assessed by transcranial doppler, suggesting that cerebral blood flow was maintained during the treatment period.

1. Rashid P, Leonardi-Bee J, Weaver C, Bath F, Bath P, The effect of transdermal glyceryl trinitrate on blood

pressure and middle cerebral artery velocity in acute stroke. Cerebrovasc Dis 2002; 13(suppl 3):p.53.

### ENOS FUNDING SUCCESS

We are pleased to announce a successful funding application from The Hypertension Trust, a UK based charity. This will support an ENOS sub-study assessing the effects of GTN patches on cerebral blood flow, measured using xenon CT, in stroke patients.

Similarly, ENOS has received invitations for a full submission for funding the start-up phase of the trial from the Health Technology Assessment Group (a government agency) and PPP health care.

### CONGRATULATIONS

Congratulations to our three new UK centres in Bishop Auckland, Cheltenham and Nottingham Queens Medical Centre. We would like to welcome them to the ENOS trial and we wish them well in recruiting their first patients shortly. As always, we welcome other interested sites to fax, email or post the form which is attached with this newsletter to the ENOS trial office (addresses below). Alternatively, you can access this form at the ENOS trial website.

### ENOS RECRUITMENT

NOTTINGHAM CITY HOSPITAL 27 PATIENTS	NOTTINGHAM, QUEEN'S MEDICAL CENTRE 0 PATIENTS
SINGAPORE GENERAL HOSPITAL 7 PATIENTS	BISHOP AUCKLAND GENERAL HOSPITAL 0 PATIENTS
GLAN CLWYD GENERAL HOSPITAL 0 PATIENTS	DELANCEY HOSPITAL, CHELTENHAM 0 PATIENTS